


Treatment outcomes of Bedaquiline-exposed tuberculosis patients treated with a regimen containing bedaquiline and delamanid: findings from MSF clinic, Mumbai, India

Hiyani Mongia¹, Homa Mansoor¹, Fatima Mamnoon¹, Arunima Silsarma¹, Praveen Davuluri¹, VijayChavan¹, Samsuddin Khan¹, Pramila Singh¹, Aparna Iyer¹, Mabel Morales¹, Alpa Dalal², Gabriella Ferlazzo³, Petros Isaakidis³
¹Médecins Sans Frontières (MSF), Mumbai, India; ²Jupiter Hospital, Mumbai, India; ³MSF, Cape Town, South Africa

- **Mumbai, India: High proportion of MDR-TB with FQ resistance**
- **BDQ extension available conditionally**
- **Descriptive study in MSF clinic, Mumbai, India**
- **Oct, 2017 to Oct, 2020: DR-TB patients with prolonged BDQ exposure (>=6 month) with**
- **Failure to culture convert in IP**
- **Reversion to culture positive post BDQ completion**
- **Requiring regimen strengthening**

56% unsuccessful outcome of BDQ exposed patients treated with BDQ and DLM regimen

BDQ exposed patients have poor treatment outcomes despite salvage regimen. Even with 32% successful outcomes, the quality of life is hampered due to extensive lung damage.



Demography	Variable	Characteristics	N (%)
	Age (in years)	Median (range)	23 (16-58)
	Sex	Female	20 (59%)
Baseline information	Inclusion criteria	C/S +ve at end of 6 month	25 (73%)
		C/S +ve at after 6 month (reversion)	7 (21%)
		Strengthening regimen	2 (5%)
	Site of disease	PTB	31 (91%)
	Resistance pattern	Pre-XDR	26 (76%)
XDR		8 (24%)	
Co-morbidity	HIV	1 (3%)	
Pulmonary involvement	Bilateral	30 (88%)	

treatment outcomes of BDQ exposed patients treated with BDQ and DLM based regimen



- **Poor treatment outcomes of BDQ exposed patients**
- **Upfront BDQ and DLM needed with BDQ extension in DRTB hotspots**
- **Access to BDQ DST required**
- **R&D for new DRTB drugs required**

We would like to acknowledge our patients and their families.